Transfer Factor in the Treatment of Herpes Simplex Types 1 and 2

Khan, Amanullah; Hansen, B.; Hill, Norwood O.; Loeb, Ellen; Pardue, A; Hill, Joseph M.

doi:10.1159/000250157

Cited by 18 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before the advent of AIDS, genital herpes was a rapidly spreading sexually transmitted disease (STD), and probably this was one of the reasons to be one of the first human viruses treated by TF. The preliminary observations of Khan et al, 30 who reported excellent results in 17 patients with recurrent infection using a TF with not-defined antigenic specificity, were confirmed by Dwyer.…”

Section: Herpes Simplexmentioning

confidence: 75%

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Levine

Pizza²,

Ajmera³

et al. 2011

Advances in Tumor Virology

View full text Add to dashboard Cite

Abstract:Transfer factor (TF) is a lymphocyte extract of low molecular weight capable of transferring antigen-specific information to T-lymphocytes. A number of reports have documented its efficacy in the control of acute viral infections, particularly those associated with herpes viruses. There have been also several reports of clinical trials utilizing Epstein-Barr Virus-specific TF in associated malignancies, particularly Burkitt's lymphoma and nasopharyngeal carcinoma. One of the more important advances in the field has been the ability to produce standardized TF in tissue culture or by animal immunization, allowing the opportunity to develop well-controlled clinical trials, and the possibility to replicate them in independent studies. This review discusses the studies that have provided the best information regarding the efficacy of TF in fighting viral infections and suggests areas where clinical trials could be most useful, such as the prevention of human papilloma virus induced cervical cancer and human T-cell lymphotropic virus induced adult T-cell leukemia/ lymphoma.

show abstract

Section: Herpes Simplexmentioning

confidence: 75%

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Levine

Pizza²,

Ajmera³

et al. 2011

Advances in Tumor Virology

View full text Add to dashboard Cite

show abstract

“…Taking into account the possible undergoing immunodepression, various immunomodulating agents could be another possible option for acute and long-term prophylactic treatment. Several synthetic and natural immunomodulators with possible antiviral activities were studied in the treatment and prevention of labial herpes simplex with various efficacies, including inosine pranobex [34], transfer factors [35][36][37][38], topical honey [39], lysine [40], vitamin C [41], and zinc [42]. Biologically active polysaccharides, including β-glucans, represent one of the most studied group of natural substances with many beneficial biological activities useful in the management and prevention of various pathological conditions of infectious and noninfectious origin.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Pleuran (β‐Glucan from Pleurotus ostreatus) in the Management of Herpes Simplex Virus Type 1 Infection

Urbancikova

Hudackova²,

Majtán

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

One of the highly prevalent viral pathogens among children and adults causing infection, clinically presenting as herpes labialis, is herpes simplex virus type 1 (HSV-1). The long-term administration of acyclovir, a standard regimen for therapy against HSV-1 infections, can cause viral resistance against this drug. Therefore, the development of natural drugs with low toxicity that are able to enhance host antiviral defense against HSV infection is needed. β-Glucans represent a type of biologically active molecules possessing antiviral properties. The goal of this study was to investigate the clinical and immunomodulatory effect of β-glucan pleuran (insoluble β-1,3/1,6-D-glucan isolated from Pleurotus ostreatus) based supplements on the duration and intensity of herpes symptoms and on the incidence rate and duration of acute respiratory symptoms and intercurrent diseases in HSV-1 positive patients. Ninety patients were randomised into active and placebo groups. Active treatment with pleuran in systemic application caused a significantly shorter duration of herpes simplex symptoms compared to the placebo group. During the preventive phase (120 days), the duration and severity of respiratory symptoms were lower in the active group compared to the placebo group; however, a significant difference was found only in the case of cough. No significant side effects were observed during both phases of the clinical trial (acute and preventive). Obtained results suggest that the use of pleuran seems to be a promising approach in the treatment of acute HSV-1 with beneficial effect on the respiratory tract symptoms and infections.

show abstract

“…Khan et al [54] were the first to treat HSV with specific TF. In 1981, 16 patients suffering from recurrent herpes-HSV-1 (cold sores) and HSV-2 (genital) were injected with TF on a weekly or monthly basis.…”

Section: Herpesvirus Infectionsmentioning

confidence: 99%

Immunotherapy with Dialyzable Leukocyte Extracts Containing Transfer Factor

Arnaudov¹

2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

Dialyzable leukocyte extracts (DLE) are complexes consisting of a large number of low molecular weight substances. These extracts possess immunomodulatory properties, which are mainly attributed to small peptides with molecular weight of 3.5-6.0 kDa called "transfer factor." This chapter reviews the nature and immunological characteristics of DLE containing transfer factor (TF), their mechanism of action and the possible uses as immunomodulators in human and veterinary medicine. A main advantage of TF-preparations as immunotherapeutic agents is that they induce a rapid immune response against the pathogen (within 24 h) and thereby reduce the time for the patient immune response by 9-13 days. The low level of difficulty of the process of obtaining protocols determines their relatively low cost and the possibility to combine them with other therapeutic agents during treatment makes them subject to medical applications in the future, including against some new diseases.

show abstract

Transfer Factor in the Treatment of Herpes Simplex Types 1 and 2

Cited by 18 publications

References 5 publications

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Efficacy of Pleuran (β‐Glucan from Pleurotus ostreatus) in the Management of Herpes Simplex Virus Type 1 Infection

Immunotherapy with Dialyzable Leukocyte Extracts Containing Transfer Factor

Contact Info

Product

Resources

About